Treatment of Low-Risk Gestational Trophoblastic Neoplasia
Author:
- 1 March 2011
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 29 (7) , 786-788
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Phase III Trial of Weekly Methotrexate or Pulsed Dactinomycin for Low-Risk Gestational Trophoblastic Neoplasia: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2011
- Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasiaInternational Journal of Gynecology & Obstetrics, 2009
- Multiplex short tandem repeat DNA analysis confirms the accuracy of p57KIP2 immunostaining in the diagnosis of complete hydatidiform moleHuman Pathology, 2006
- Low-Risk Persistent Gestational Trophoblastic Disease: Outcome After Initial Treatment With Low-Dose Methotrexate and Folinic Acid From 1992 to 2000Journal of Clinical Oncology, 2002
- The new FIGO 2000 staging and risk factor scoring system for gestational trophoblastic disease: Description and critical assessmentInternational Journal of Gynecological Cancer, 2001
- Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 yearsEuropean Journal of Cancer, 1998
- Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors.Journal of Clinical Oncology, 1996
- Single-agent methotrexate chemotherapy for the treatment of nonmetastatic gestational trophoblastic tumorsAmerican Journal of Obstetrics and Gynecology, 1995
- 5-Day Methotrexate for Women with Metastatic Gestational Trophoblastic DiseaseGynecologic Oncology, 1994
- The role of low‐dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT)BJOG: An International Journal of Obstetrics & Gynaecology, 1989